A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine

BACKGROUND: DFN-02 is a novel intranasal spray formulation composed of sumatriptan 10 mg and a permeation-enhancing excipient comprised of 0.2% 1-O-n-Dodecyl-β-D-Maltopyranoside (DDM). This composition of DFN-02 allows sumatriptan to be rapidly absorbed into the systemic circulation and exhibit phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Munjal, Sagar, Brand-Schieber, Elimor, Allenby, Kent, Spierings, Egilius L.H., Cady, Roger K., Rapoport, Alan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332324/
https://www.ncbi.nlm.nih.gov/pubmed/28251391
http://dx.doi.org/10.1186/s10194-017-0740-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332324/
https://www.ncbi.nlm.nih.gov/pubmed/28251391
http://dx.doi.org/10.1186/s10194-017-0740-3

Ejemplares similares